Physician profile
Casmiar I Nwaigwe
NPI 1902832041
$39,444.93
in general payments reported to CMS, 2019-2025
22 companies · $21K in 2025
The $21K reported for 2025 was more than what 96% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $491 · 2020: $89.03 · 2021: $356 · 2022: $298 · 2023: $11K · 2024: $6,395 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Travel and Lodging: $7,505 · Food and Beverage: $1,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,268.75 |
| Travel and Lodging | $7,505.32 |
| Food and Beverage | $1,436.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $38,516.82 | 2019-2025 | Rezzayo, Kimyrsa, Orbactiv |
| T2 Biosystems, INC. | $225.17 | 2019 | |
| Abbvie INC. | $130.02 | 2020-2024 | |
| Astellas Pharma US INC | $99.00 | 2019 | |
| Kerecis Limited | $84.03 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Merck Sharp & Dohme LLC | $61.41 | 2019-2024 | Delstrigo, Dificid |
| Gilead Sciences, INC. | $49.27 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $46.68 | 2024-2025 | |
| Davol INC. | $41.71 | 2019 | |
| Horizon Therapeutics Plc | $37.76 | 2021-2023 | Actimmune |
| Ferring Pharmaceuticals INC. | $36.85 | 2022-2023 | Rebyota |
| Aimmune Therapeutics, INC. | $20.09 | 2024 | |
| Pfizer INC. | $16.67 | 2019 | |
| Insmed, INC. | $16.24 | 2022 | |
| Nabriva Therapeutics, Plc | $14.37 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $13.62 | 2020 | |
| Tetraphase Pharmaceuticals, INC. | $13.39 | 2019 | |
| Tactile Systems Technology INC | $11.15 | 2020 | |
| Echosens North America, INC. | $10.68 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casmiar Nwaigwe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.